Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
复制标题
DOI：
10.1093/eurheartj/ehaa006
复制
发表时间：
2020-05-07
影响因子：
39.3
通讯作者：
Lopez Fernandez, Teresa
中科院分区：
文献类型：
--
作者：
Lopez-Sendon, Jose;Alvarez-Ortega, Carlos;Lopez Fernandez, Teresa
目的心脏毒性（CTox）是癌症治疗的主要副作用，但缺乏统一的诊断标准来指导临床和研究实践。方法与结果前瞻性研究865例患者，年龄54.7 +/- 13.9；16.3%的男性，计划接受与中/高CTox风险相关的抗癌治疗。根据目前的指南考虑四组进行性心肌损伤/功能障碍：正常、正常生物标志物（高敏感性肌钙蛋白T和n端利钠前肽）和左心室（LV）功能；轻度，生物标志物异常，和/或左室功能障碍（LVD）维持左室射血分数(LVEF) >= 50%；中度，LVD, LVEF 40-49%；严重的，LVD伴LVEF
Aim Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking.Methods and results We prospectively studied 865 patients, aged 54.7 +/- 13.9; 16.3% men, scheduled for anticancer therapy related with moderate/high CTox risk. Four groups of progressive myocardial damage/dysfunction were considered according to current guidelines: normal, normal biomarkers (high-sensitivity troponin T and N-terminal natriuretic pro-peptide), and left ventricular (LV) function; mild, abnormal biomarkers, and/or LV dysfunction (LVD) maintaining an LV ejection fraction (LVEF) >= 50%; moderate, LVD with LVEF 40-49%; and severe, LVD with LVEF